These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 28594749

  • 1. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
    Schachtner T, Stein M, Reinke P.
    Transplantation; 2017 Oct; 101(10):e315-e325. PubMed ID: 28594749
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D, Cesaro S, Cofano S, Fiscon M, Saldan A, Varotto S, Mengoli C, Pillon M, Calore E, Biasolo MA, Cusinato R, Barzon L, Messina C, Carli M, Palù G.
    Transplantation; 2012 Mar 15; 93(5):536-42. PubMed ID: 22314338
    [Abstract] [Full Text] [Related]

  • 4. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
    Chanouzas D, Small A, Borrows R, Ball S.
    PLoS One; 2018 Mar 15; 13(3):e0193968. PubMed ID: 29558479
    [Abstract] [Full Text] [Related]

  • 5. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
    Abate D, Saldan A, Mengoli C, Fiscon M, Silvestre C, Fallico L, Peracchi M, Furian L, Cusinato R, Bonfante L, Rossi B, Marchini F, Sgarabotto D, Rigotti P, Palù G.
    J Clin Microbiol; 2013 Aug 15; 51(8):2501-7. PubMed ID: 23678073
    [Abstract] [Full Text] [Related]

  • 6. Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors.
    Schachtner T, Stein M, Reinke P.
    Transpl Infect Dis; 2017 Jun 15; 19(3):. PubMed ID: 28296035
    [Abstract] [Full Text] [Related]

  • 7. Kidney transplant recipients after nonrenal solid organ transplantation show low alloreactivity but an increased risk of infection.
    Schachtner T, Stein M, Reinke P.
    Transpl Int; 2016 Dec 15; 29(12):1296-1306. PubMed ID: 27638250
    [Abstract] [Full Text] [Related]

  • 8. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
    Tarasewicz A, Dębska-Ślizień A, Rutkowski B.
    Transplant Proc; 2016 Jun 15; 48(5):1650-3. PubMed ID: 27496465
    [Abstract] [Full Text] [Related]

  • 9. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
    Favi E, Santangelo R, Iesari S, Morandi M, Marcovecchio GE, Trecarichi EM, Salerno MP, Ferraresso M, Citterio F, Romagnoli J.
    Transplant Proc; 2017 Oct 15; 49(8):1766-1772. PubMed ID: 28923622
    [Abstract] [Full Text] [Related]

  • 10. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
    Johnson RJ, Clatworthy MR, Birch R, Hammad A, Bradley JA.
    Transplantation; 2009 Jul 15; 88(1):77-82. PubMed ID: 19584684
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S.
    Transplantation; 2010 Nov 27; 90(10):1091-8. PubMed ID: 20885340
    [Abstract] [Full Text] [Related]

  • 12. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H, Mutlu E, Köksoy S, Yılmaz VT, Koçak H, Çolak D, Mutlu D, Günseren F, Dinçkan A, Aliosmanoğlu İ, Süleymanlar G, Gültekin M.
    Mikrobiyol Bul; 2016 Apr 27; 50(2):224-35. PubMed ID: 27175495
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B.
    J Immunol Methods; 2014 Jun 27; 408():101-13. PubMed ID: 24877879
    [Abstract] [Full Text] [Related]

  • 14. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.
    Kaminski H, Jarque M, Halfon M, Taton B, Di Ascia L, Pfirmann P, Visentin J, Garrigue I, Déchanet-Merville J, Moreau JF, Crespo E, Montero N, Melilli E, Meneghini M, Pascual M, Couzi L, Manuel O, Bestard O, Merville P.
    J Infect Dis; 2019 Jul 31; 220(5):761-771. PubMed ID: 31157865
    [Abstract] [Full Text] [Related]

  • 15. The Loss of BKV-specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication.
    Schachtner T, Stein M, Babel N, Reinke P.
    Am J Transplant; 2015 Aug 31; 15(8):2159-69. PubMed ID: 25808077
    [Abstract] [Full Text] [Related]

  • 16. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.
    Chiereghin A, Gabrielli L, Zanfi C, Petrisli E, Lauro A, Piccirilli G, Baccolini F, Dazzi A, Cescon M, Morelli MC, Pinna AD, Landini MP, Lazzarotto T.
    Transplant Proc; 2010 Aug 31; 42(1):69-73. PubMed ID: 20172283
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, Ekser B, Biasolo MA, Cusinato R, Mengoli C, Bonfante L, Rossi B, Rigotti P, Sgarabotto D, Barzon L, Palù G.
    J Infect Dis; 2010 Aug 15; 202(4):585-94. PubMed ID: 20594105
    [Abstract] [Full Text] [Related]

  • 18. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.
    Jarque M, Melilli E, Crespo E, Manonelles A, Montero N, Torras J, Cruzado JM, Luque S, Gil-Vernet S, Grinyó JM, Bestard O.
    Transplantation; 2018 Nov 15; 102(11):e472-e480. PubMed ID: 30130330
    [Abstract] [Full Text] [Related]

  • 19. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 20. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients.
    Lúcia M, Crespo E, Melilli E, Cruzado JM, Luque S, Llaudó I, Niubó J, Torras J, Fernandez N, Grinyó JM, Bestard O.
    Clin Infect Dis; 2014 Dec 01; 59(11):1537-45. PubMed ID: 25048845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.